Aldosterone blockade in post-acute myocardial infarction heart failure

Clinical Cardiology

Volumn 29, Issue 10, 2006, Pages 434-438

  Pitt, Bertram ^a   Ferrari, Roberto ^b   Gheorghiade, Mihai ^c   Van Veldhuisen, Dirk J ^d   Krum, Henry ^e   McMurray, John ^f   Lopez Sendon, Jose ^g  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Aldosterone; EPHESUS; Eplerenone; Heart failure; Left ventricular systolic dysfunction; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; NITRIC ACID DERIVATIVE; SPIRONOLACTONE;

ACUTE HEART INFARCTION; ALGORITHM; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DRUG EFFICACY; DRUG MONITORING; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REPERFUSION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPOTENSION; MORBIDITY; MORTALITY; PATIENT CARE; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 33749613169     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960291004     Document Type: Review

References (26)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321
3. Steg PG, Dabbous OH, Feldman LJ, and the Global Registry of Acute Coronary Events Investigators: Determinants and prognostic impact of heart failure complicating acute coronary syndromes: Observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004;109:494-499
4. Wu AH, Parsons L, Every NR, Bates ER, for the Second National Registry of Myocardial Infarction: Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 2002;40:1389-1394
5. Moller JE, Brendorp B, Ottesen M, Kober L, Egstrup K, Poulsen SH, Torp-Pedersen C: Congestive heart failure with preserved left ventricular systolic function after acute myocardial infarction: Clinical and prognostic implications. Eur J Heart Fail 2003;5:811-819
6. Abildstrom SZ, Ottesen MM, Rask-Madsen C, Andersen PK, Rosthoj S, Torp-Pedersen C, Kober L: Sudden cardiovascular death following myocardial infarction: The importance of left ventricular systolic dysfunction and congestive heart failure. Int J Cardiol 2005;104:184-189
7. Goldberg RJ, Spencer FA, Yarzebski J, Lessard D, Gore JM, Alpert JS, Dalen JE: A 25-year perspective into the changing landscape of patients hospitalized with acute myocardial infarction (the Worcester Heart Attack Study). Am J Cardiol 2004;94:1373-1378
8. Solomon SD, Zelenkofske S, McMurray JJV, Finn PV, Velazquez E, Ertl G, Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, Van de Werf F, Pieper K, Califf RM, Pfeffer MA, for the Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators: Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352:2581-2588
9. De Angelis N, Fiordaliso F, Latini R: Appraisal of the role of angiotensin II and aldosterone in ventricularmyocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol 2002;34:1655-1665
10. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K: Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol 1995;290:69-73
11. Brilla CG, Zhou G, Matsubara L, Weber KT: Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-820
12. Joffe HV, Adler GK: Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005;10:31-37
13. Ferner E, Kerfant BG, Lalevee N, Bideaux P, Rossier MF, Richard S, Gomez AM, Benitah JP: Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 2004;110:776-783
14. Suzuki G, Monta H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967-2972
15. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J: Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003;42:1666-1673
16. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J, on behalf of the EPHESUS Investigators: Eplerenone reduces mortality 30 days post-randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46:425-431
17. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ; and the DINAMIT Investigators: Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-2488
18. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr., Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction- executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588-636
19. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Dates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2005;112:1825-1852
20. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ: Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140
21. Banas J, White H, Parkhomenko A, Patni R, Mukherjee R, Zannad F: Favorable outcomes with 25 mg of eplerenone in patients with post-AMI heart failure: Results from the EPHESUS trial. J Cardiac Fail 2005;11 (6 suppl):S156
22. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;352:543-551
23. McMurray JJ, O'Meara E: Treatment of heart failure with spironolactone-trial and tribulations. N Engl J Med 2004;351:526-528
24. Pitt B: Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 2003;108:1790-1794
25. Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B: Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction. Circulation 2005;111:1106-1113
26. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH: Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP). Am J Cardiol 2001;87:819-822